Barriers to medical device innovation

被引:64
作者
Bergsland, Jacob [1 ]
Elle, Ole Jakob [1 ]
Fosse, Erik [1 ]
机构
[1] Univ Oslo, Oslo Univ Hosp, Intervent Ctr, Inst Clin Med, Oslo, Norway
关键词
implantable; FDA; regulation; CE-mark; innovation;
D O I
10.2147/MDER.S43369
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
The US Food and Drug Administration (FDA) has defined a medical device as a health care product that does not achieve it's purpose by chemical action or by being metabolized. This means that a vast number of products are considered medical devices. Such devices play an essential role in the practice of medicine. The FDA classifies medical devices in three classes, depending on the risk of the device. Since Class I and II devices have relatively simple requirements for getting to the market, this review will focus on "implantable devices", which, in general, belong to Class III. The European Union and Canada use a slightly different classification system. While early generations of medical devices were introduced without much testing, either technical or clinical, the process of introducing a Class III medical device from concept to clinical practice has become strongly regulated and requires extensive technological and clinical testing. The modern era of implantable medical devices may be considered to have started in the 1920s with development of artificial hips. The implantable pacemaker was another milestone and pacemakers and cardioverters/defibrillators have since saved millions of lives and created commercial giants in the medical device industry. This review will include some examples of cardiovascular devices. Similar considerations apply to the total implantable device market, although clinical and technological applications obviously vary considerably.
引用
收藏
页码:205 / 209
页数:5
相关论文
共 38 条
[1]   Treatment of endstage heart disease with mechanical circulatory assistance [J].
Argenziano, M ;
DeRose, JJ ;
Oz, MC ;
Rose, EA .
JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1997, 61 (11) :887-892
[2]   Intraoperative and intermediate-term angiographic results of coronary artery bypass surgery with symmetry proximal anastomotic device [J].
Bergsland, J ;
Hol, PK ;
Lingås, PS ;
Lundblad, R ;
Rein, KA ;
Andersen, R ;
Mork, BE ;
Halvorsen, S ;
Mujanovic, E ;
Kabil, E ;
Svennevig, JL ;
Fosse, E .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2004, 128 (05) :718-723
[3]   Twenty-five-year experience with the Bjork-Shiley convexoconcave heart valve - A continuing clinical concern [J].
Blot, WJ ;
Ibrahim, MA ;
Ivey, TD ;
Acheson, DE ;
Brookmeyer, R ;
Weyman, A ;
Defauw, J ;
Smith, JK ;
Harrison, D .
CIRCULATION, 2005, 111 (21) :2850-2857
[4]   Relationships between academic institutions and industry in the life sciences - An industry survey [J].
Blumenthal, D ;
Causino, N ;
Campbell, E ;
Louis, KS .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (06) :368-373
[5]   Physician-Industry Cooperation In The Medical Device Industry [J].
Chatterji, Aaron K. ;
Fabrizio, Kira R. ;
Mitchell, Will ;
Schulman, Kevin A. .
HEALTH AFFAIRS, 2008, 27 (06) :1532-1543
[6]   FDA'S Perspectives on Cardiovascular Devices [J].
Chen, Eric A. ;
Patel-Raman, Sonna M. ;
O'Callaghan, Kathryn ;
Hillebrenner, Matthew G. .
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2009, 2 (02) :143-146
[7]  
Crisp S, 1996, Proc Inst Mech Eng H, V210, P233
[8]   Innovative technology-transcatheter aortic valve implantation: Cost and reimbursement issues [J].
Dahle, Gry ;
Rein, Kjell Arne ;
Fiane, Arnt ;
Fosse, Erik ;
Khushi, Ishtiaq ;
Hagen, Terje ;
Mishra, Vinod .
SCANDINAVIAN CARDIOVASCULAR JOURNAL, 2012, 46 (06) :345-352
[9]   STRUT FRACTURE AND DISK EMBOLIZATION IN BJORK-SHILEY MITRAL-VALVE PROSTHESES - DIAGNOSIS AND MANAGEMENT [J].
DAVIS, PK ;
MYERS, JL ;
PENNOCK, JL ;
THIELE, BL .
ANNALS OF THORACIC SURGERY, 1985, 40 (01) :65-68
[10]   The Emperor's New Clothes II-time for regulators to wake up and take responsibility for unnecessary asthma morbidity: time for the second aerosol 'transition' [J].
Everard, Mark L. .
THORAX, 2013, 68 (09) :891-893